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With respect to research advances, rheumatoid arthritis (RA)
has evolved from being largely neglected about a dozen years
ago to being one of the most fascinating diseases in
medicine. There are a variety of reasons for this
metamorphosis, mostly related to renewed interest in
studying the many biological facets of the disease, to
developments in clinical and basic research, and to
stimulation by the results obtained. First, RA develops as a
combination of an inflammatory process – synovitis – with a
‘semimalignant’ event, namely the transgression of tissue
boundaries characteristic of this erosive disease; although
the full details of this transformation remain enigmatic, some
important aspects have been elucidated [1,2]. Second, RA
involves an autoimmune component, the role of which in the
pathogenic cascade is at least a disease-aggravating one
[3,4], although this is yet to be sufficiently clarified.
Autoimmunity frequently precedes the development of clinical
symptoms by many years [5], suggesting an essential or at
least closely associated role in pathogenesis, but there is also
a slow evolution of the disease through states of ‘pre-arthritis’
and ‘very early arthritis’. Third, novel, validated and
reproducible techniques have been developed and used to
assess changes in clinical variables and progression of joint
destruction [6,7]. Fourth, even though RA is presumably an
incurable disorder and traditional disease-modifying
antirheumatic drugs, which slow the progression of RA,
usually have limited efficacy in established disease [8], these
agents appear to be highly effective in very early RA,
suggesting that there exists a window of opportunity during
which disease can be controlled in many patients [9]. Finally,
RA has been a major area for investigations into the efficacy
and safety of innovative therapies that target particular cell
surface, cell secreted and intracellular molecules [10]. This
has not only permitted new treatment options to be realized in
clinical practice but it has also yielded insights into the
enormously complex pathogenesis of the disease.
Treatment of RA has undergone dramatic changes with the
widespread application of sufficiently high doses of
methotrexate [11,12] and with the remarkable efficacy of a
biological agent targeting tumour necrosis factor (TNF)
[1,13]. Long-term prognosis in RA depends on interference
with the destructive process, because over time increasing
damage will result in greater functional loss [14]. In this
respect the TNF blockers appear to have even greater
efficacy in retarding the process of erosion than their effect
on clinical abnormalities reflecting synovitis [15,16]. The
initial findings on the efficacy of TNF inhibition not only have
encouraged the development of additional TNF blockers for
use in RA, but they have also stimulated studies in other
chronic inflammatory disorders, many of which yielded highly
positive results.
TNF blockade represents an important advance but it is not
the ultimate solution to RA therapy, which has stimulated
further research into other potential molecules involved in RA
pathogenesis and clinical trials targeting such molecules.
Evidently, other proinflammatory cytokines, such as IL-1 and
IL-6, are such targets. An IL-1 anatagonist, anakinra, is
already approved, although its efficacy appears to be less
than that of TNF blockade [17]; other IL-1 blockers are
currently being tested. Phase II trials of an IL-6 blocker,
tocilizumab, have also been conducted [18]. Given the
autoimmune basis of RA, which is manifested by the
production of rheumatoid factor and other autoantibodies and
by their association with disease severity, B cells also
represent a potential target; in fact, rituximab (anti-CD20) has
also proven to be efficacious in phase II trials [19].
A novel therapeutic principle is discussed in this supplement
to Arthritis Research & Therapy, namely modulation of co-
stimulation. Co-stimulation, as detailed in the three reviews in
the supplement, is an essential step in the induction of the
adaptive immune response, which centres around T cell
activation. T cells have long been regarded as essential in the
initial phases of RA. However, despite evidence of lympho-
kine production, even in established disease [20], failure of
some T-cell directed therapies to improve long-standing RA
[21], as well as the profound efficacy of agents targeting
proinflammatory cytokines mostly produced by non-T-cells
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such as TNF, suggested that T cells play no or only a minor
role in perpetuating the disease. Skapenko and coworkers
(pp S4-S14) revisit the importance and various aspects of the
role played by T cells in RA.
The apparent efficacy of interference with co-stimulation using
CTLA4–Ig (cytotoxic T lymphocyte-associated antigen 4–-
immunoglobulin; abatacept) [22] has restored T cells to a
central position in RA, even late RA. The detailed
consequences of blocking the interaction between CD80/86
and CD28 in RA still require study, in particular because co-
stimulatory pathways other than CD28-mediated ones remain
unaffected. The effects of modulating co-stimulation might
involve reduction in the intercellular crosstalk that is needed
for the activation of macrophages and other cell populations
[23] as well as reduction in B-cell activating capacity, directly
by interfering with T cell help or via induction of regulatory T
cells, which appear to be deficient in RA [24]. Malmström and
coworkers (pp S15-S20) discuss the importance of co-
stimulation and the possible consequences of its modification.
As Ruderman and Pope review (pp S21-S25), clinical
responses to abatacept in phase II and phase III trials were
similar to those with other biological agents such as the TNF
blockers, rituximab and tocilizumab. Trials with these agents
found a large number of American College of Rheumatology
(ACR) 20 responders, a fair number of ACR 50 responders
and relatively few true remissions. Because the biologics
target different molecules (various proinflammatory cytokines,
a B-cell surface molecule [CD20] and a co-stimulatory
molecule expressed on T cells), these are interesting results.
Does this mean that many targets are of equal importance?
Does it mean that we can eliminate one element of the
‘inflammatory house of cards’ [10], consistently having some
effect but rarely with full collapse of the inflammatory
process? What does this tell us about the pathobiology of
RA?
Another interesting observation is the importance of
combining biological agents with methotrexate; for most
biologicals such combination therapy is superior to either
agent alone. What is the role played by methotrexate in this
context? Does it merely change the pharmacokinetics of
biological compounds or does it have a synergistic effect?
Despite the enhancement in effect yielded by combination
with methotrexate, even better responses would be welcome;
could a combination of two biological agents (with or without
methotrexate) more frequently result in remission or even
cure? Could abatacept – which, as Ruderman and Pope
reveal, is also efficacious in patients who fail to respond to
TNF blockers – represent a major component of such
combination therapy? These are questions that must be
addressed in future trials.
It is generally gratifying to witness the emergence of new
treatment principles from theoretical indications to reality –
from the realm of basic sciences to successful clinical trials
showing efficacy and safety, and subsequently to clinical
practice and long-term use. This has been especially so for
RA, a disease with frequently devastating and long-term
consequences for those affected, whose fate has already
improved significantly over recent years and will hopefully
improve further. However, this is also true for many other
immuno-inflammatory disorders, in which innovative therapies
were pioneered by advances made in our field.
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